Published in Neurosurg Clin N Am on January 01, 2010
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer (GBM) | NCT00045968
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas | NCT00766753
Vaccine Therapy in Treating Patients With Malignant Glioma | NCT00068510
Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma | NCT00576641
Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol (2011) 1.24
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol (2011) 1.07
Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol (2012) 1.05
Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs (2012) 1.03
Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci (2011) 0.86
Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy. Biomed Res Int (2014) 0.86
Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro Oncol (2015) 0.85
Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children. Onco Targets Ther (2014) 0.83
Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma. J Biol Chem (2014) 0.82
TRP-ing up brain tumors. Nat Med (2012) 0.76
Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. Onco Targets Ther (2016) 0.75
Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol (2016) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature (1985) 8.23
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Stat proteins and oncogenesis. J Clin Invest (2002) 4.79
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res (2000) 4.79
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Specific inhibition of Stat3 signal transduction by PIAS3. Science (1997) 4.74
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res (2003) 3.25
Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res (2005) 3.07
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res (1996) 3.00
Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med (1993) 2.96
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res (2004) 2.89
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86
Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene (2002) 2.69
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol (2006) 2.53
Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res (2003) 2.45
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene (2006) 2.37
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A (2003) 2.35
Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J (1987) 2.23
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res (1990) 2.15
Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells. J Immunol (2007) 2.01
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ (1995) 2.00
Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol (1994) 1.98
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92
An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol (2006) 1.92
A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res (2007) 1.91
Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer (2003) 1.85
Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res (2008) 1.80
Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol (1989) 1.79
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery (2007) 1.74
Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg (2006) 1.73
Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther (2004) 1.70
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer (2007) 1.64
The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res (2008) 1.62
T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J (1987) 1.59
Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci (2003) 1.58
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res (2004) 1.57
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A (2003) 1.56
Stress-induced proteins in immune response to cancer. Curr Top Microbiol Immunol (1991) 1.56
Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One (2008) 1.49
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol (2008) 1.47
Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res (2002) 1.42
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides (2007) 1.40
Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem (2000) 1.39
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol (2007) 1.38
Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol (2005) 1.37
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A (2000) 1.32
Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest (1993) 1.30
Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer (2004) 1.28
Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Expert Rev Anticancer Ther (2007) 1.27
Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer (2002) 1.27
Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol (2000) 1.26
Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur J Immunol (2002) 1.26
Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg (1995) 1.25
Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol (2003) 1.23
Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery (2002) 1.23
Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem Biophys Res Commun (2005) 1.22
Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia (2009) 1.21
Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function. Eur J Immunol (2007) 1.20
Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol (1994) 1.19
Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells. J Immunol (2000) 1.19
Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci (2003) 1.17
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother (2005) 1.17
Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol (2004) 1.17
Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol (1999) 1.16
Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res (2005) 1.16
Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother (1997) 1.16
Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus (2000) 1.16
Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J Immunol (2002) 1.15
Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res (2006) 1.12
EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene (2003) 1.11
Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther (2005) 1.11
Carbon monoxide promotes Fas/CD95-induced apoptosis in Jurkat cells. J Biol Chem (2004) 1.10
T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res (2000) 1.08
Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer (2000) 1.06
Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer (1995) 1.06
CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep (2005) 1.05
Dihydroxy-2,5 benzenesulphonate (dobesilate) elicits growth arrest and apoptosis in glioma cells. Neurol Res (2005) 1.03
In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res (2001) 1.02
A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer (2001) 1.02
Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol (2004) 1.02
Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res (2004) 1.01
Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol (1995) 1.00
Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol (1996) 0.99
Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer (1994) 0.99
DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs (2009) 0.98
Differential expressions of heme oxygenase-1 gene in CD25- and CD25+ subsets of human CD4+ T cells. Biochem Biophys Res Commun (2003) 0.98
Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res (1986) 0.96
Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol (2006) 0.96
Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol (2008) 0.95
Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery (2006) 0.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nat Mater (2009) 2.02
An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol (2006) 1.92
Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol (2011) 1.89
Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells (2008) 1.74
Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg (2006) 1.73
Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res (2012) 1.67
Chemokines in tumor progression and metastasis. Oncotarget (2013) 1.64
IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res (2012) 1.55
Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther (2007) 1.48
Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther (2011) 1.39
CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol (2007) 1.35
Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res (2008) 1.30
Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med (2010) 1.28
A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm (2011) 1.27
Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Expert Rev Anticancer Ther (2007) 1.27
Mechanisms of immune evasion by gliomas. Adv Exp Med Biol (2012) 1.26
Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia (2006) 1.26
The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry (2012) 1.24
PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res (2010) 1.23
The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg (2006) 1.21
A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst (2013) 1.21
A high-performance nanobio photocatalyst for targeted brain cancer therapy. Nano Lett (2009) 1.19
The role of regulatory T cells in malignant glioma. Anticancer Res (2008) 1.18
WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med (2013) 1.17
Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med (2007) 1.15
The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther (2010) 1.15
The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget (2011) 1.10
The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One (2010) 1.09
Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS One (2010) 1.08
CD46 represents a target for adenoviral gene therapy of malignant glioma. Hum Gene Ther (2006) 1.07
Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use. Stem Cells Transl Med (2013) 1.07
Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther (2007) 1.05
Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther (2010) 1.04
Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs (2012) 1.03
Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther (2010) 1.02
Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. Int J Oncol (2009) 1.02
A tractography comparison between turboprop and spin-echo echo-planar diffusion tensor imaging. Neuroimage (2008) 1.02
Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr Drug Deliv (2007) 1.01
Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials (2013) 1.00
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Front Immunol (2013) 0.99
The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther (2010) 0.98
Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Hum Gene Ther (2007) 0.98
Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy. Small (2013) 0.97
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett (2011) 0.97
Targeted therapies for malignant glioma: progress and potential. BioDrugs (2009) 0.97
Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol Biol (2012) 0.97
The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother (2015) 0.96
Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice. Front Oncol (2013) 0.95
Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma? Oncotarget (2013) 0.93
Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. J Neurosurg (2007) 0.92
Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus. Mol Cancer Ther (2006) 0.92
Therapeutic cell carriers: a potential road to cure glioma. Expert Rev Neurother (2014) 0.91
The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Transl Med (2013) 0.91
Role of craniotomy in the management of pituitary adenomas and sellar/parasellar tumors. Expert Rev Anticancer Ther (2006) 0.91
Virotherapy against malignant glioma stem cells. Cancer Lett (2009) 0.91
Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy. J Med Virol (2008) 0.91
Oncolytic adenoviral therapy for glioblastoma multiforme. Neurosurg Focus (2006) 0.90
Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. J Tissue Eng Regen Med (2010) 0.90
Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies. Expert Rev Neurother (2013) 0.89
Cancer stem cells: the final frontier for glioma virotherapy. Stem Cell Rev (2011) 0.89
The expression of BST2 in human and experimental mouse brain tumors. Exp Mol Pathol (2011) 0.88
Gene therapy trials for the treatment of high-grade gliomas. Gene Ther Mol Biol (2007) 0.88
Adenoviral virotherapy for malignant brain tumors. Expert Opin Biol Ther (2009) 0.88
Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2. J Biol Chem (2012) 0.88
Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia (2010) 0.88
A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery. J Clin Neurosci (2012) 0.86
A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. Anticancer Drugs (2008) 0.86
New therapeutic approaches for malignant glioma: in search of the Rosetta stone. F1000 Med Rep (2012) 0.86
Conditionally replicative adenoviral vectors for malignant glioma. Rev Med Virol (2006) 0.86
The role of IDO in brain tumor immunotherapy. J Neurooncol (2014) 0.86
Targeted therapy for malignant glioma: neural stem cells. Expert Rev Neurother (2006) 0.86
N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy. Mol Ther (2013) 0.85
Surgical management of high-grade gliomas. Expert Rev Neurother (2005) 0.85
Glioblastoma multiforme: can neural stem cells deliver the therapeutic payload and fulfill the clinical promise? Expert Rev Neurother (2011) 0.85
An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy. Int J Oncol (2007) 0.84
Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma. J Neurooncol (2005) 0.84
Crossing the boundaries: stem cells and gene therapy. Discov Med (2010) 0.83
Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions. Expert Rev Neurother (2005) 0.83
Cancer cell death by design: apoptosis, autophagy and glioma virotherapy. Autophagy (2009) 0.83
A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy. J Gene Med (2009) 0.83
Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small (2014) 0.83
Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells. PLoS One (2011) 0.82
Advances in stem cells, induced pluripotent stem cells, and engineered cells: delivery vehicles for anti-glioma therapy. Expert Opin Drug Deliv (2014) 0.82
Current immunotherapeutic strategies for central nervous system tumors. Surg Oncol Clin N Am (2007) 0.82
Stem cells as delivery vehicles for oncolytic adenoviral virotherapy. Curr Gene Ther (2009) 0.82
The art of attraction: applications of multifunctional magnetic nanomaterials for malignant glioma. Expert Opin Drug Deliv (2014) 0.82
Regulatory T cells actively infiltrate metastatic brain tumors. Int J Oncol (2009) 0.82
Vector therapies for malignant glioma: shifting the clinical paradigm. Expert Opin Drug Deliv (2008) 0.81
Immunotherapy for glioblastoma: the devil is in the details. J Clin Oncol (2011) 0.81
Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. CNS Oncol (2014) 0.81
Progression of intracranial glioma disrupts thymic homeostasis and induces T-cell apoptosis in vivo. Cancer Immunol Immunother (2008) 0.80
Immunotherapy for malignant glioma: current approaches and future directions. Neurol Res (2005) 0.80
Neural stem cell-mediated delivery of oncolytic adenovirus. Curr Protoc Hum Genet (2015) 0.79
Clinical significance of KISS1 protein expression for brain invasion and metastasis. Cancer (2011) 0.78